400 related articles for article (PubMed ID: 18529047)
1. Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors.
Peifer C; Selig R; Kinkel K; Ott D; Totzke F; Schächtele C; Heidenreich R; Röcken M; Schollmeyer D; Laufer S
J Med Chem; 2008 Jul; 51(13):3814-24. PubMed ID: 18529047
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors.
Peifer C; Stoiber T; Unger E; Totzke F; Schächtele C; Marmé D; Brenk R; Klebe G; Schollmeyer D; Dannhardt G
J Med Chem; 2006 Feb; 49(4):1271-81. PubMed ID: 16480264
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and characterization of N9/N7-substituted 6-aminopurines as VEGF-R and EGF-R inhibitors.
Peifer C; Bühler S; Hauser D; Kinkel K; Totzke F; Schächtele C; Laufer S
Eur J Med Chem; 2009 Apr; 44(4):1788-93. PubMed ID: 18524423
[TBL] [Abstract][Full Text] [Related]
4. Profile and molecular modeling of 3-(indole-3-yl)-4-(3,4,5-trimethoxyphenyl)-1 H-pyrrole-2,5-dione (1) as a highly selective VEGF-R2/3 inhibitor.
Peifer C; Krasowski A; Hämmerle N; Kohlbacher O; Dannhardt G; Totzke F; Schächtele C; Laufer S
J Med Chem; 2006 Dec; 49(25):7549-53. PubMed ID: 17149885
[TBL] [Abstract][Full Text] [Related]
5. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.
Gingrich DE; Reddy DR; Iqbal MA; Singh J; Aimone LD; Angeles TS; Albom M; Yang S; Ator MA; Meyer SL; Robinson C; Ruggeri BA; Dionne CA; Vaught JL; Mallamo JP; Hudkins RL
J Med Chem; 2003 Dec; 46(25):5375-88. PubMed ID: 14640546
[TBL] [Abstract][Full Text] [Related]
6. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel angiogenesis inhibitors.
Sridhar J; Akula N; Sivanesan D; Narasimhan M; Rathinavelu A; Pattabiraman N
Bioorg Med Chem Lett; 2005 Sep; 15(18):4125-9. PubMed ID: 15993586
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design and synthesis of pyrrole derivatives as MEK inhibitors.
Wallace MB; Adams ME; Kanouni T; Mol CD; Dougan DR; Feher VA; O'Connell SM; Shi L; Halkowycz P; Dong Q
Bioorg Med Chem Lett; 2010 Jul; 20(14):4156-8. PubMed ID: 20621728
[TBL] [Abstract][Full Text] [Related]
9. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Chem Biol Drug Des; 2007 Mar; 69(3):204-11. PubMed ID: 17441906
[TBL] [Abstract][Full Text] [Related]
10. Pyrrole derivatives as potent inhibitors of lymphocyte-specific kinase: Structure, synthesis, and SAR.
Takayama T; Umemiya H; Amada H; Yabuuchi T; Shiozawa F; Katakai H; Takaoka A; Yamaguchi A; Endo M; Sato M
Bioorg Med Chem Lett; 2010 Jan; 20(1):108-11. PubMed ID: 19945869
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents.
Abadi AH; Abou-Seri SM; Abdel-Rahman DE; Klein C; Lozach O; Meijer L
Eur J Med Chem; 2006 Mar; 41(3):296-305. PubMed ID: 16494969
[TBL] [Abstract][Full Text] [Related]
12. Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.
La DS; Belzile J; Bready JV; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn JC; Flynn SR; Graceffa RF; Harriman SP; Larrow JF; Long AM; Martin MW; Morrison MJ; Patel VF; Roveto PM; Wang L; Weiss MM; Whittington DA; Teffera Y; Zhao Z; Polverino AJ; Harmange JC
J Med Chem; 2008 Mar; 51(6):1695-705. PubMed ID: 18311900
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel taspine derivatives as antiangiogenic agents.
Zhang J; Zhang Y; Zhang S; Wang S; He L
Bioorg Med Chem Lett; 2010 Jan; 20(2):718-21. PubMed ID: 20006929
[TBL] [Abstract][Full Text] [Related]
14. Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase.
Piatnitski EL; Duncton MA; Kiselyov AS; Katoch-Rouse R; Sherman D; Milligan DL; Balagtas C; Wong WC; Kawakami J; Doody JF
Bioorg Med Chem Lett; 2005 Nov; 15(21):4696-8. PubMed ID: 16143524
[TBL] [Abstract][Full Text] [Related]
15. Molecular modeling study and synthesis of novel pyrrolo[2,3-d]pyrimidines and pyrrolotriazolopyrimidines of expected antitumor and radioprotective activities.
Abou El Ella DA; Ghorab MM; Noaman E; Heiba HI; Khalil AI
Bioorg Med Chem; 2008 Mar; 16(5):2391-402. PubMed ID: 18086527
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases.
Dandu R; Zulli AL; Bacon ER; Underiner T; Robinson C; Chang H; Miknyoczki S; Grobelny J; Ruggeri BA; Yang S; Albom MS; Angeles TS; Aimone LD; Hudkins RL
Bioorg Med Chem Lett; 2008 Mar; 18(6):1916-21. PubMed ID: 18308565
[TBL] [Abstract][Full Text] [Related]
17. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.
Harris PA; Boloor A; Cheung M; Kumar R; Crosby RM; Davis-Ward RG; Epperly AH; Hinkle KW; Hunter RN; Johnson JH; Knick VB; Laudeman CP; Luttrell DK; Mook RA; Nolte RT; Rudolph SK; Szewczyk JR; Truesdale AT; Veal JM; Wang L; Stafford JA
J Med Chem; 2008 Aug; 51(15):4632-40. PubMed ID: 18620382
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.
Weiss MM; Harmange JC; Polverino AJ; Bauer D; Berry L; Berry V; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1668-80. PubMed ID: 18324759
[TBL] [Abstract][Full Text] [Related]
19. Rational design, structure, and biological evaluation of cyclic peptides mimicking the vascular endothelial growth factor.
Goncalves V; Gautier B; Coric P; Bouaziz S; Lenoir C; Garbay C; Vidal M; Inguimbert N
J Med Chem; 2007 Oct; 50(21):5135-46. PubMed ID: 17900101
[TBL] [Abstract][Full Text] [Related]
20. Identification of 2-anilino-9-methoxy-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones as dual PLK1/VEGF-R2 kinase inhibitor chemotypes by structure-based lead generation.
Egert-Schmidt AM; Dreher J; Dunkel U; Kohfeld S; Preu L; Weber H; Ehlert JE; Mutschler B; Totzke F; Schächtele C; Kubbutat MH; Baumann K; Kunick C
J Med Chem; 2010 Mar; 53(6):2433-42. PubMed ID: 20170163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
